Anticholinergic burden and polypharmacy in hospitalized urology patients: Prevalence and clinical implications

ABSTRACT Background: The increasing prevalence of polypharmacy and cumulative anticholinergic burden (ACB) in hospitalized patients represents a major concern for drug safety and pharmacological risk management. This study evaluated the prevalence and predictors of polypharmacy and ACB in urology inpatient population, with a focus on pharmacological classification of anticholinergic exposure. Materials and Methods: A retrospective cohort study was conducted among 500 consecutive patients admitted to a tertiary urology department between September 2024 and March 2025. Data were extracted from the electronic medical records, including demographics, clinical diagnoses, and prescribed medications. Polypharmacy was defined as ≥5 concurrent medications. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden (ACB) Scale, with scores ≥3 considered high risk. Results: The cohort had a mean age of 61.7 ± 14.2 years and was predominantly male (81.6%). Polypharmacy was observed in 40.6% of the patients, with significantly higher prevalence in those ≥50 years (47.1% vs. 9.3%; odds ratio = 6.88, 95% confidence interval: 4.09–18.43). Anticholinergic medications were prescribed to 71.4% of the patients, with 25.6% classified as high-risk (ACB ≥3). Pharmacological subgroup analysis revealed frequent exposure to cardiovascular, psychotropic, neurological, and urological agents with anticholinergic properties. Older age was associated with higher ACB scores ( P = 0.043). No significant sex differences were observed in the prevalence of polypharmacy ( P = 0.06) or ACB burden ( P > 0.05). Conclusions: Urology inpatients, particularly older adults, demonstrate high rates of polypharmacy and pharmacologically significant anticholinergic exposure. These findings underscore the importance of pharmacological vigilance, rational prescribing, and deprescribing strategies to mitigate drug-related adverse outcomes in hospitalized population.

Authors

Institutions

Publication Details

Journal
Indian Journal of Urology
Published
2026-03-27
DOI
https://doi.org/10.4103/iju.iju_524_25
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anticholinergic burden and polypharmacy in hospitalized urology patients: Prevalence and clinical implications

Berat Sönmez, Eyüp Dil, Görkem Akça, Yakup Kaçan et al.
Indian Journal of Urology
Pharmaceutical Practices and Patient Outcomes
article

Anticholinergic burden and polypharmacy in hospitalized urology patients: Prevalence and clinical implications

Berat Sönmez, Eyüp Dil, Görkem Akça, Yakup Kaçan, Erdem Orman, Hakki Uzun
article en

Abstract

ABSTRACT Background: The increasing prevalence of polypharmacy and cumulative anticholinergic burden (ACB) in hospitalized patients represents a major concern for drug safety and pharmacological risk management. This study evaluated the prevalence and predictors of polypharmacy and ACB in urology inpatient population, with a focus on pharmacological classification of anticholinergic exposure. Materials and Methods: A retrospective cohort study was conducted among 500 consecutive patients admitted to a tertiary urology department between September 2024 and March 2025. Data were extracted from the electronic medical records, including demographics, clinical diagnoses, and prescribed medications. Polypharmacy was defined as ≥5 concurrent medications. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden (ACB) Scale, with scores ≥3 considered high risk. Results: The cohort had a mean age of 61.7 ± 14.2 years and was predominantly male (81.6%). Polypharmacy was observed in 40.6% of the patients, with significantly higher prevalence in those ≥50 years (47.1% vs. 9.3%; odds ratio = 6.88, 95% confidence interval: 4.09–18.43). Anticholinergic medications were prescribed to 71.4% of the patients, with 25.6% classified as high-risk (ACB ≥3). Pharmacological subgroup analysis revealed frequent exposure to cardiovascular, psychotropic, neurological, and urological agents with anticholinergic properties. Older age was associated with higher ACB scores ( P = 0.043). No significant sex differences were observed in the prevalence of polypharmacy ( P = 0.06) or ACB burden ( P > 0.05). Conclusions: Urology inpatients, particularly older adults, demonstrate high rates of polypharmacy and pharmacologically significant anticholinergic exposure. These findings underscore the importance of pharmacological vigilance, rational prescribing, and deprescribing strategies to mitigate drug-related adverse outcomes in hospitalized population.

Indian Journal of UrologyVol. 42(2)
Recep Tayyip Erdoğan University (TR)
Good health and well-being
Openalex Percentile: Top 4%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.